About the company
Thank you for visiting AffyXell Therapeutics Co., Ltd.
AffyXell Therapeutics Co., Ltd. (CEO: Seungho Jeon, and Jong Sang Ryu)
is a next-generation cell & gene therapy development company founded
in January 23rd, 2020 as a joint venture by Daewoong Pharmaceuticals
and Avacta Life Science, U.K.
We are developing next generation cell & gene therapeutics (AFX platform technology) for optimized for immunomodulation of diseases. The AFX platform technology is new modality of cell & gene therapeutics that based on advanced mesenchymal stem cells which to overcome the limitations of tissue-derived mesenchymal stem cells and adopted Affimer platform technology by genetic manipulations for improve immunomodulation function.